| 1 |
33597189 | Interferon-β Is Less Effective Than Other Drugs in Controlling the Rate of Retinal Ganglion Cell Loss in MS. | 2021 May |
1 |
| 2 |
29139001 | The Assessment for Disinvestment of Intramuscular Interferon Beta for Relapsing-Remitting Multiple Sclerosis in Brazil. | 2018 Feb |
1 |
| 3 |
30075406 | Pediatric-onset multiple sclerosis in Brazilian patients: Clinical features, treatment response and comparison to pediatric neuromyelitis optica spectrum disorders. | 2018 Oct |
1 |
| 4 |
27063624 | Long-term impact of interferon or Glatiramer acetate in multiple sclerosis: A systematic review and meta-analysis. | 2016 Mar |
1 |
| 5 |
25646307 | IFN-β treatment requires B cells for efficacy in neuroautoimmunity. | 2015 Mar 1 |
1 |
| 6 |
26374509 | Overview of the management of relapsing-remitting multiple sclerosis and practical recommendations. | 2015 Oct |
1 |
| 7 |
26475277 | Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study. | 2015 Dec |
2 |
| 8 |
25170258 | Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing-remitting multiple sclerosis treatment. | 2014 |
1 |
| 9 |
25182864 | Current perspectives on interferon Beta-1b for the treatment of multiple sclerosis. | 2014 Sep |
1 |
| 10 |
22133480 | Spasticity improvement in patients with relapsing-remitting multiple sclerosis switching from interferon-β to glatiramer acetate: the Escala Study. | 2012 Apr 15 |
4 |
| 11 |
23650472 | Clinical utility of glatiramer acetate in the management of relapse frequency in multiple sclerosis. | 2012 |
1 |
| 12 |
20456216 | Current and future disease-modifying therapies in multiple sclerosis. | 2010 Apr |
1 |
| 13 |
20637960 | Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study. | 2010 Jun |
1 |
| 14 |
19200865 | Multiple sclerosis beyond EDSS: depression and fatigue. | 2009 Feb 1 |
1 |
| 15 |
19921551 | [Glatiramer acetate in interferon beta non respondent relapsing-remitting multiple sclerosis]. | 2009 Sep |
1 |
| 16 |
18164542 | The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews. | 2008 Nov |
1 |
| 17 |
18690500 | Glatiramer acetate is a treatment option in neutralising antibodies to interferon-beta-positive patients. | 2008 Sep |
3 |
| 18 |
16674604 | Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients. | 2006 Jun |
2 |
| 19 |
16146492 | The efficacy of glatiramer acetate in beta-interferon-intolerant MS patients. | 2005 Oct |
2 |
| 20 |
17516727 | Cost-analysis of relapsing-remitting multiple sclerosis in Italy after the introduction of new disease-modifying agents. | 2004 |
2 |
| 21 |
12521562 | Disease-modifying Therapies for Multiple Sclerosis. | 2003 Jan |
1 |
| 22 |
12835817 | [Cost-utility analisys of multiple sclerosis treatment with glatiramer acetate or interferon beta in Spain]. | 2003 May-Jun |
1 |
| 23 |
12349849 | Differential mechanisms of action of interferon-beta and glatiramer aetate in MS. | 2002 Sep 24 |
2 |
| 24 |
12474988 | Effect of combined IFNbeta-1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis. | 2002 Dec |
2 |
| 25 |
12581542 | A comparison of the mechanisms of action of interferon beta and glatiramer acetate in the treatment of multiple sclerosis. | 2002 Dec |
1 |